Physiologically Based Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Analysis for Ceftriaxone Dosing in Pregnant Women: Model Development and Clinical Applications

breakpoint (2.81→1.75 µg/mL at 1 g q.d.; 5.61→3.50 µg/mL at 2 g q.d.), quantifying the pharmacodynamic margin under standard regimens. This transparent, reproducible modeling framework provides quantitative support for reconsidering pregnancy dosing strategies and advances precision medicine approaches in obstetric pharmacotherapy during the ongoing maternal syphilis public health crisis.